近日， 陕西云谷众惠生物医药有限公司 （以下简称"众惠医药"）完成了种子轮及天使轮融资，总金额 近5000万元 。种子轮融资由 昕成投资、爱康创坛 联合投 资，天使轮融资则由 陕投成长基金、中科创星、金资基金 联合投资。此轮融资将用于 中国首家 空心微针医疗器械生产基地建设、三类器械证申报、细胞与外泌体 中试车间建设、 西北首个 自动化生物组织样本库建设以及人才队伍的完善。 同时，众惠医药宣布完成对 上海揽微医学科技有限公司 的并购重组。 # 关于 众惠医药 | 思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | | --- | --- | --- | | 即将召开： | | | | 2025年6月12日，首届全球医美科技大会 | | | | 2025年7月17日，第二届全球医疗科技大会 | | | | 2025年9月4-5日，第三届全球手术机器人大会 | | | 此外，众惠医药还推出了 首款 具备生发功能的基因编辑工程化干细胞 ，依托正在建设的" 西北首个自动化生物组织样本库 "，公司可实现细胞与基因等生物资源 的长期保藏和科学研究。公司研发的外泌体裹挟药物靶向传递技术， ...

Company Performance - SurModics reported a quarterly loss of $0.13 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.06, and a decline from earnings of $0.07 per share a year ago, resulting in an earnings surprise of -116.67% [1] - The company posted revenues of $28.09 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 8.73%, and down from $31.96 million in the same quarter last year [2] - SurModics has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates two times in the same period [2] Stock Performance - SurModics shares have declined approximately 21.9% since the beginning of the year, compared to a decline of 5.5% for the S&P 500 [3] - The current Zacks Rank for SurModics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.01 on revenues of $30.47 million, and for the current fiscal year, it is -$0.01 on revenues of $124.01 million [7] - The estimate revisions trend for SurModics is mixed, and changes in earnings expectations may occur following the recent earnings report [6] Industry Context - The Medical - Products industry, to which SurModics belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact SurModics' stock performance [5]